About ViaCyte

Developing leading cell replacement therapies to functionally cure human diseases

Headquartered in San Diego, ViaCyte is a regenerative medicine company focused on the discovery, development, and commercialization of novel cell replacement therapies to treat human diseases. We are a leader in the field advancing stem cell-derived islet cell replacement therapies to treat insulin-requiring diabetes, including type 1 and type 2.

The Company’s leadership is reflected in its robust intellectual property portfolio, which includes hundreds of issued patents and pending applications worldwide.

With more than two decades of research and expertise in the field, two product candidates in clinical trials, and a third in preclinical development, ViaCyte believes it has the key elements needed to produce transformative therapies for all people who require insulin to treat diabetes.

ViaCyte’s Breakthrough Research

ViaCyte’s history of leadership and firsts in developing stem cell-derived cell replacement therapies for type 1 diabetes.

Based on published scientific literature, the Company’s scientists were the first to describe directed differentiation of human pluripotent stem cells into pancreatic endoderm cells (PEC) and the first to demonstrate the potential of these cells to faithfully produce insulin in response to increased blood glucose in preclinical models. ViaCyte has shown that PEC cells further differentiate in vivo, in both preclinical and clinical studies, to the constituent cell types of the human pancreatic islet.

Science

47

Peer-reviewed scientific publications

Leadership

27

Average years of experience (Average of 9 years with ViaCyte)

Grants

>$85.9M

From CIRM and JDRF

 

$72.3M CIRM + $13.6M JDRF + more

Patents

550

Worldwide Patents

90 United States 400 Additional Pending Worldwide

Clinical

1st

ever clinical trials for a stem cell-derived cell replacement therapy for diabetes

Technologies

ViaCyte has two product candidates, PEC-Encap and PEC-Direct, in clinical development for the treatment of type 1 diabetes. The Company’s third program, PEC-QT, in preclinical development to potentially treat all insulin-requiring type 1 and type 2 diabetes, is partnered with CRISPR Therapeutics.

ViaCyte’s innovative product candidates are based on two technology platforms: 1) stem cell expansion and differentiation, and 2) implantable devices for cell delivery (including the Encaptra® system). For the PEC family of product candidates, ViaCyte differentiates pluripotent stem cells into pancreatic islet precursors (PEC-01 cells). For PEC-Encap, the PEC-01 cells are then placed within the Encaptra system and implanted subcutaneously. Once implanted, the PEC-01 cells are designed to mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels, as endocrine cells do in a healthy functioning human pancreas.

Our technology platforms have the potential to yield treatments for other diseases that are caused by a loss or malfunction of a specific cell or tissue type. Because our platforms represent two major technological advances (stem cell-derived cell replacement therapies and the Encaptra system), we have opportunities to use each individually or together to address critical human diseases and disorders that can potentially be treated by replacing lost or malfunctioning cells or proteins.


At ViaCyte, our mission is to profoundly improve the lives of people with type 1 diabetes. To accomplish that, we have become leaders and pioneers in many areas, breaking new ground in stem cell research and medical device engineering, and developing brand new methods of cell therapy scaling and manufacturing.

Our Leadership

We believe that ViaCyte has all of the elements it needs to successfully deliver transformative cell therapies for insulin-requiring diabetes, including cell and device platform technologies, know-how, expertise, intellectual property, and regulatory, clinical, and manufacturing experience. The experience and expertise of our team is integral to ViaCyte’s advancement of transformative cell replacement therapies as possible functional cures for human diseases and the realization of the potential of our proprietary technologies.

With breakthrough technology, clinical stage product candidates, an extensive intellectual property estate, and a strong and dedicated team, ViaCyte has all the pieces to advance transformative cell replacement therapies for diabetes.

Sign up for updates

To have our press releases and major updates sent to you, please provide your name and email address.